Next Generation Medicine 2026 brings 60+ speakers to Dubai’s longevity market

Dubai will host Next Generation Medicine 2026 from 7 to 10 November 2026 at Atlantis The Royal, putting longevity, regenerative medicine and precision health in front of clinics, insurers, investors and patients in a market where regulation is now moving faster than provider marketing.

The immediate audience is private outpatient groups, aesthetic and wellness clinics, hospital medical directors and payer teams. For Dubai operators, the relevant regulator is the Dubai Health Authority (DHA). In Abu Dhabi and Al Ain, it is the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, operators should check Ministry of Health and Prevention (MOHAP) facility rules and Emirates Drug Establishment requirements for pharmaceutical products.

What Dubai is hosting

Gulf News reported on 23 September 2026 that AEON Clinic will host the four-day congress under Dr Jaffer Khan. The event site says the programme includes 60+ expert speakers, four fully programmed days and participants from 20+ countries, with tracks on biomarkers of ageing, genomics, multi-omics, cellular senescence, exosomes, orthobiologics, regenerative ophthalmology, AI decision support and digital twins.

“From Evidence to Adoption — Building the Clinic of 2030 Today.” — Next Generation Medicine 2026 programme theme, cited by Gulf News

The commercial signal is plain. Longevity is being packaged as a clinic model, not only a conference topic. Dubai also created the Dubai Longevity Authority under Law No. (17) of 2026, which defines activities covering preventive, regenerative and advanced therapeutic products. For CEOs, that means the sector is becoming investable. For COOs, it means the paperwork burden will rise.

Why clinics and insurers should care

Regenerative medicine in Dubai is not an unregulated wellness add-on. DHA issued Standards for Stem Cell Services with an effective date of 28 February 2026. The standard says clinical applications must follow DHA regulations, UAE federal law and recognised medical, scientific and ethical standards. It also requires evidence of safety, efficacy, scientific rationale, informed consent, clinical appropriateness and regulatory authorisation.

That changes the operating question for clinics. The issue is whether a service can be advertised, consented, billed, sourced and audited under the correct licence. A clinic selling exosomes, cell-based interventions, biologics, advanced diagnostics or hormonal longevity programmes should be able to show four files before launch:

• Facility and professional licence scope under DHA, DOH or MOHAP.
• Product sourcing, storage and dispensing records where a medicine, biologic or medical product is involved.
• Patient consent forms that separate established care from investigational or elective services.
• Payer pre-authorisation rules for Daman, Thiqa, Sukoon or any other contracted insurer.

For CFOs, the actionable number is reimbursement certainty, not the retail price printed on a brochure. Many longevity services combine physician consultations, lab panels, imaging, injectables, supplements and follow-up reviews. UAE operators should price these through their own tariff file, payer contract and pre-authorisation portal. If a service lacks a covered indication, it should be treated as self-pay until the insurer confirms otherwise in writing.

What patients will ask next

Patients will hear four terms after this congress: longevity, regenerative care, precision health and biological age. Clinics should expect demand for blood panels, genomic risk assessment, GLP-1-linked metabolic programmes, musculoskeletal injections, hair and skin procedures, fertility-related longevity advice and menopause or andrology services. The responsible answer starts with eligibility, diagnosis and regulator-approved scope, then moves to price.

Abu Dhabi already has a more research-led signal. DOH announced on 12 April 2025 the completion of a clinical trial in Abu Dhabi involving mesenchymal stem cells for knee osteoarthritis, in collaboration with Cellcolabs and Burjeel Holdings. That does not create blanket approval for all stem cell services. It shows how the emirate wants advanced therapies to move through licensed research, ethics review and regulator oversight.

For pharmacy operators, the event matters because more clinics will need compliant supply chains for prescription medicines, supplements, cold-chain products and specialist biologics. Pharmacists should check whether each product is registered, imported through the right channel and dispensed by a licensed provider. Claims about anti-ageing, cellular repair or regenerative effects should match approved labelling and clinical evidence.

The next practical step is due diligence. Before referring patients or forming a partnership, operators should verify the provider licence, medical director, pharmacy licence, payer status and product route. Zavis readers can use the UAE Open Healthcare Directory to find licensed pharmacy providers and compare verified healthcare listings across Dubai, Abu Dhabi and the northern emirates.